Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
LivaNova ( (LIVN) ) just unveiled an announcement.
LivaNova PLC is currently involved in a legal dispute regarding environmental liabilities inherited through its merger with Sorin. On March 14, 2025, the Italian Supreme Court referred the case back to the Court of Appeal, leading the company to record a liability of €333.3 million. Despite a filing by the Ministry of Ecological Transition challenging this decision, LivaNova intends to defend its position and maintain its current financial guidance for 2025.
The most recent analyst rating on (LIVN) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on LivaNova stock, see the LIVN Stock Forecast page.
Spark’s Take on LIVN Stock
According to Spark, TipRanks’ AI Analyst, LIVN is a Neutral.
LivaNova’s stock score reflects solid revenue growth and technical momentum. However, profitability issues and significant liabilities weigh on its financial performance and valuation. The earnings call highlighted both strategic successes and legal challenges, balancing optimism with caution.
To see Spark’s full report on LIVN stock, click here.
More about LivaNova
LivaNova PLC is a company operating in the medical technology industry, primarily focusing on the development of devices for cardiac surgery and neuromodulation. The company was formed through a merger with Sorin and is involved in providing innovative healthcare solutions.
Average Trading Volume: 902,812
Technical Sentiment Signal: Sell
Current Market Cap: $2.4B
Learn more about LIVN stock on TipRanks’ Stock Analysis page.